04:34 PM EDT, 08/08/2024 (MT Newswires) -- Cytokinetics ( CYTK ) reported a Q2 loss late Thursday of $1.31 per diluted share, narrower than the loss of $1.34 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.94.
Revenue for the quarter ended June 30 was $249,000, down from $867,000 a year earlier.
Analysts surveyed by Capital IQ expected about $21 million.